Drug Design and Optimization

This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

 

In order to combat the increasing number of resistant pathogens, the development of new antibiotic drugs is an important goal for pharmaceutical research. Lacking in this field are efficient medications that fight infectious diseases. As a result, scientists are constructing and improving novel agents that target essential processes in bacteria. This is done with the aim of killing or attenuating these pathogens. Below, you may read more about the optimization of new drug candidates.

  • Prof Dr Rolf W. Hartmann

    Rolf Hartmann

    Head of the Department Drug Design and Optimization

    +49 681 98806-2000

    + 49 681 98806-2009

    Contact

    CV and Publications

  • May Concepcion Sena Küffner

    May Concepcion Sena Kueffner DDOP

    Assistant to the Department Head

    +49 681 98806-2001

    +49 0681 98806-2009

    Contact

  • Dr Jörg Haupenthal

    Joerg Haupenthal

    Scientist

    +49 681 98806-2011

    Contact

  • Dr Martin Empting

    Martin Empting

    Postdoc

    +49 681 98806-2031

    Contact

  • Dr Mostafa Hamed

    Mostafa Hamed

    Post-Doc

    +49 681 98806-2022

    Contact

  • Dr Christine Maurer

    Christine Maurer

    Post-Doc

    +49 681 98806-2032

    Contact

  • Dr Samir Yahiaoui

    Postdoc

    0681-98806-2021

    Contact

  • Giuseppe Allegretta

    Allegretta Giuseppe DDOP 0030

    PhD Student

    +49 0681 98806-2062

    Contact

  • Ahmed Kamal

    Kamal Ahmed DDOP 0032

    PhD Student

    +49 681 98806-2061

    Contact

  • Andreas Kany

    Andreas Kany

    PhD Student

    +49 681 98806-2051

    Contact

Leader

  • Prof Dr Rolf W. Hartmann

    Rolf Hartmann

    Head of the Department Drug Design and Optimization

    +49 681 98806-2000

    + 49 681 98806-2009

    Contact

    CV and Publications

News

Bachelor & Master
Are you interested in a bachelor or master thesis? We are looking forward to your request!

Audio Podcast

  • Kündigung für Biofilm-WGs – Pharmazeuten des HIPS stören Bakteriengemeinschaften
    Bakterien haben einen ausgeprägten Gemeinschaftssinn und verschanzen sich gerne in schleimigen Biofilmen. Etwa 60 Prozent aller bakteriellen Infektionen lösen inzwischen Biofilme aus. Ein besonders geselliger Keim ist Pseudomonas aeruginosa. Er ist besonders für Mukoviszidose-Patienten gefährlich. Wissenschaftler am Helmholtz-Institut für Pharmazeutische Forschung Saarland suchen nach Wegen, seine Biofilme aufzulösen – damit Medikamente wirken können. Begleiten Sie Anke Steinbach in Ihre Labore...